nodes	percent_of_prediction	percent_of_DWPC	metapath
Betahistine—Digestion impaired—Fludarabine—lymphatic system cancer	0.0407	0.0407	CcSEcCtD
Betahistine—Epigastric pain—Mitoxantrone—lymphatic system cancer	0.0335	0.0335	CcSEcCtD
Betahistine—Erythema multiforme—Mechlorethamine—lymphatic system cancer	0.02	0.02	CcSEcCtD
Betahistine—Bronchospasm—Teniposide—lymphatic system cancer	0.0191	0.0191	CcSEcCtD
Betahistine—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.0155	0.0155	CcSEcCtD
Betahistine—Stevens-Johnson syndrome—Fludarabine—lymphatic system cancer	0.0151	0.0151	CcSEcCtD
Betahistine—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.015	0.015	CcSEcCtD
Betahistine—Skin disorder—Mechlorethamine—lymphatic system cancer	0.0146	0.0146	CcSEcCtD
Betahistine—Erythema multiforme—Fludarabine—lymphatic system cancer	0.0129	0.0129	CcSEcCtD
Betahistine—Bronchospasm—Bleomycin—lymphatic system cancer	0.0123	0.0123	CcSEcCtD
Betahistine—Confusional state—Teniposide—lymphatic system cancer	0.0111	0.0111	CcSEcCtD
Betahistine—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.011	0.011	CcSEcCtD
Betahistine—Ill-defined disorder—Fludarabine—lymphatic system cancer	0.011	0.011	CcSEcCtD
Betahistine—Tachycardia—Teniposide—lymphatic system cancer	0.0108	0.0108	CcSEcCtD
Betahistine—Abdominal pain upper—Mitoxantrone—lymphatic system cancer	0.0107	0.0107	CcSEcCtD
Betahistine—Malaise—Fludarabine—lymphatic system cancer	0.0107	0.0107	CcSEcCtD
Betahistine—Pruritus—Mechlorethamine—lymphatic system cancer	0.0106	0.0106	CcSEcCtD
Betahistine—Convulsion—Fludarabine—lymphatic system cancer	0.0103	0.0103	CcSEcCtD
Betahistine—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.0103	0.0103	CcSEcCtD
Betahistine—Discomfort—Fludarabine—lymphatic system cancer	0.01	0.01	CcSEcCtD
Betahistine—Dyspnoea—Teniposide—lymphatic system cancer	0.00985	0.00985	CcSEcCtD
Betahistine—Confusional state—Fludarabine—lymphatic system cancer	0.0098	0.0098	CcSEcCtD
Betahistine—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00972	0.00972	CcSEcCtD
Betahistine—Vomiting—Mechlorethamine—lymphatic system cancer	0.00953	0.00953	CcSEcCtD
Betahistine—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00953	0.00953	CcSEcCtD
Betahistine—Rash—Mechlorethamine—lymphatic system cancer	0.00945	0.00945	CcSEcCtD
Betahistine—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00945	0.00945	CcSEcCtD
Betahistine—Feeling abnormal—Teniposide—lymphatic system cancer	0.00911	0.00911	CcSEcCtD
Betahistine—Nausea—Mechlorethamine—lymphatic system cancer	0.00891	0.00891	CcSEcCtD
Betahistine—Urticaria—Teniposide—lymphatic system cancer	0.00878	0.00878	CcSEcCtD
Betahistine—Hallucination—Carmustine—lymphatic system cancer	0.00871	0.00871	CcSEcCtD
Betahistine—Dyspnoea—Fludarabine—lymphatic system cancer	0.00866	0.00866	CcSEcCtD
Betahistine—Dyspepsia—Fludarabine—lymphatic system cancer	0.00855	0.00855	CcSEcCtD
Betahistine—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00839	0.00839	CcSEcCtD
Betahistine—Fatigue—Fludarabine—lymphatic system cancer	0.00838	0.00838	CcSEcCtD
Betahistine—Hallucination—Vincristine—lymphatic system cancer	0.00831	0.00831	CcSEcCtD
Betahistine—Hypersensitivity—Teniposide—lymphatic system cancer	0.00814	0.00814	CcSEcCtD
Betahistine—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.0081	0.0081	CcSEcCtD
Betahistine—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00801	0.00801	CcSEcCtD
Betahistine—Asthenia—Teniposide—lymphatic system cancer	0.00793	0.00793	CcSEcCtD
Betahistine—Malaise—Bleomycin—lymphatic system cancer	0.00787	0.00787	CcSEcCtD
Betahistine—Pruritus—Teniposide—lymphatic system cancer	0.00782	0.00782	CcSEcCtD
Betahistine—Diarrhoea—Teniposide—lymphatic system cancer	0.00756	0.00756	CcSEcCtD
Betahistine—Discomfort—Bleomycin—lymphatic system cancer	0.00734	0.00734	CcSEcCtD
Betahistine—Confusional state—Bleomycin—lymphatic system cancer	0.00718	0.00718	CcSEcCtD
Betahistine—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00716	0.00716	CcSEcCtD
Betahistine—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00712	0.00712	CcSEcCtD
Betahistine—Vomiting—Teniposide—lymphatic system cancer	0.00703	0.00703	CcSEcCtD
Betahistine—Asthenia—Fludarabine—lymphatic system cancer	0.00697	0.00697	CcSEcCtD
Betahistine—Rash—Teniposide—lymphatic system cancer	0.00697	0.00697	CcSEcCtD
Betahistine—Dermatitis—Teniposide—lymphatic system cancer	0.00696	0.00696	CcSEcCtD
Betahistine—Headache—Teniposide—lymphatic system cancer	0.00692	0.00692	CcSEcCtD
Betahistine—Pruritus—Fludarabine—lymphatic system cancer	0.00687	0.00687	CcSEcCtD
Betahistine—Diarrhoea—Fludarabine—lymphatic system cancer	0.00665	0.00665	CcSEcCtD
Betahistine—Convulsion—Carmustine—lymphatic system cancer	0.0066	0.0066	CcSEcCtD
Betahistine—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00657	0.00657	CcSEcCtD
Betahistine—Nausea—Teniposide—lymphatic system cancer	0.00657	0.00657	CcSEcCtD
Betahistine—Malaise—Mitoxantrone—lymphatic system cancer	0.00639	0.00639	CcSEcCtD
Betahistine—Dyspnoea—Bleomycin—lymphatic system cancer	0.00635	0.00635	CcSEcCtD
Betahistine—Convulsion—Vincristine—lymphatic system cancer	0.0063	0.0063	CcSEcCtD
Betahistine—Confusional state—Carmustine—lymphatic system cancer	0.00627	0.00627	CcSEcCtD
Betahistine—Vomiting—Fludarabine—lymphatic system cancer	0.00618	0.00618	CcSEcCtD
Betahistine—Convulsion—Mitoxantrone—lymphatic system cancer	0.00614	0.00614	CcSEcCtD
Betahistine—Rash—Fludarabine—lymphatic system cancer	0.00613	0.00613	CcSEcCtD
Betahistine—Dermatitis—Fludarabine—lymphatic system cancer	0.00612	0.00612	CcSEcCtD
Betahistine—Headache—Fludarabine—lymphatic system cancer	0.00609	0.00609	CcSEcCtD
Betahistine—Tachycardia—Carmustine—lymphatic system cancer	0.00607	0.00607	CcSEcCtD
Betahistine—Discomfort—Mitoxantrone—lymphatic system cancer	0.00596	0.00596	CcSEcCtD
Betahistine—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00594	0.00594	CcSEcCtD
Betahistine—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00587	0.00587	CcSEcCtD
Betahistine—Confusional state—Mitoxantrone—lymphatic system cancer	0.00583	0.00583	CcSEcCtD
Betahistine—Nervous system disorder—Vincristine—lymphatic system cancer	0.00582	0.00582	CcSEcCtD
Betahistine—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00578	0.00578	CcSEcCtD
Betahistine—Nausea—Fludarabine—lymphatic system cancer	0.00577	0.00577	CcSEcCtD
Betahistine—Urticaria—Bleomycin—lymphatic system cancer	0.00566	0.00566	CcSEcCtD
Betahistine—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00564	0.00564	CcSEcCtD
Betahistine—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00561	0.00561	CcSEcCtD
Betahistine—Dyspnoea—Carmustine—lymphatic system cancer	0.00554	0.00554	CcSEcCtD
Betahistine—Somnolence—Carmustine—lymphatic system cancer	0.00553	0.00553	CcSEcCtD
Betahistine—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00537	0.00537	CcSEcCtD
Betahistine—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00525	0.00525	CcSEcCtD
Betahistine—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00515	0.00515	CcSEcCtD
Betahistine—Somnolence—Mitoxantrone—lymphatic system cancer	0.00514	0.00514	CcSEcCtD
Betahistine—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00512	0.00512	CcSEcCtD
Betahistine—Feeling abnormal—Carmustine—lymphatic system cancer	0.00512	0.00512	CcSEcCtD
Betahistine—Fatigue—Vincristine—lymphatic system cancer	0.00512	0.00512	CcSEcCtD
Betahistine—Asthenia—Bleomycin—lymphatic system cancer	0.00511	0.00511	CcSEcCtD
Betahistine—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00509	0.00509	CcSEcCtD
Betahistine—Asthma—Methotrexate—lymphatic system cancer	0.00506	0.00506	CcSEcCtD
Betahistine—Pruritus—Bleomycin—lymphatic system cancer	0.00504	0.00504	CcSEcCtD
Betahistine—Fatigue—Mitoxantrone—lymphatic system cancer	0.00498	0.00498	CcSEcCtD
Betahistine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00476	0.00476	CcSEcCtD
Betahistine—Urticaria—Mitoxantrone—lymphatic system cancer	0.00459	0.00459	CcSEcCtD
Betahistine—Hypersensitivity—Carmustine—lymphatic system cancer	0.00458	0.00458	CcSEcCtD
Betahistine—Vomiting—Bleomycin—lymphatic system cancer	0.00453	0.00453	CcSEcCtD
Betahistine—Rash—Bleomycin—lymphatic system cancer	0.00449	0.00449	CcSEcCtD
Betahistine—Dermatitis—Bleomycin—lymphatic system cancer	0.00449	0.00449	CcSEcCtD
Betahistine—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.00448	0.00448	CcSEcCtD
Betahistine—Asthenia—Carmustine—lymphatic system cancer	0.00446	0.00446	CcSEcCtD
Betahistine—Hypersensitivity—Vincristine—lymphatic system cancer	0.00437	0.00437	CcSEcCtD
Betahistine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00426	0.00426	CcSEcCtD
Betahistine—Asthenia—Vincristine—lymphatic system cancer	0.00426	0.00426	CcSEcCtD
Betahistine—Diarrhoea—Carmustine—lymphatic system cancer	0.00425	0.00425	CcSEcCtD
Betahistine—Nausea—Bleomycin—lymphatic system cancer	0.00423	0.00423	CcSEcCtD
Betahistine—Asthenia—Mitoxantrone—lymphatic system cancer	0.00415	0.00415	CcSEcCtD
Betahistine—Dizziness—Carmustine—lymphatic system cancer	0.00411	0.00411	CcSEcCtD
Betahistine—Diarrhoea—Vincristine—lymphatic system cancer	0.00406	0.00406	CcSEcCtD
Betahistine—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00395	0.00395	CcSEcCtD
Betahistine—Vomiting—Carmustine—lymphatic system cancer	0.00395	0.00395	CcSEcCtD
Betahistine—Dizziness—Vincristine—lymphatic system cancer	0.00392	0.00392	CcSEcCtD
Betahistine—Rash—Carmustine—lymphatic system cancer	0.00392	0.00392	CcSEcCtD
Betahistine—Dermatitis—Carmustine—lymphatic system cancer	0.00392	0.00392	CcSEcCtD
Betahistine—Headache—Carmustine—lymphatic system cancer	0.0039	0.0039	CcSEcCtD
Betahistine—Erythema multiforme—Methotrexate—lymphatic system cancer	0.00383	0.00383	CcSEcCtD
Betahistine—Vomiting—Vincristine—lymphatic system cancer	0.00377	0.00377	CcSEcCtD
Betahistine—Rash—Vincristine—lymphatic system cancer	0.00374	0.00374	CcSEcCtD
Betahistine—Dermatitis—Vincristine—lymphatic system cancer	0.00374	0.00374	CcSEcCtD
Betahistine—Headache—Vincristine—lymphatic system cancer	0.00372	0.00372	CcSEcCtD
Betahistine—Nausea—Carmustine—lymphatic system cancer	0.00369	0.00369	CcSEcCtD
Betahistine—Vomiting—Mitoxantrone—lymphatic system cancer	0.00368	0.00368	CcSEcCtD
Betahistine—Immune system disorder—Methotrexate—lymphatic system cancer	0.00366	0.00366	CcSEcCtD
Betahistine—Rash—Mitoxantrone—lymphatic system cancer	0.00364	0.00364	CcSEcCtD
Betahistine—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00364	0.00364	CcSEcCtD
Betahistine—Headache—Mitoxantrone—lymphatic system cancer	0.00362	0.00362	CcSEcCtD
Betahistine—Nausea—Vincristine—lymphatic system cancer	0.00353	0.00353	CcSEcCtD
Betahistine—Nausea—Mitoxantrone—lymphatic system cancer	0.00343	0.00343	CcSEcCtD
Betahistine—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.00327	0.00327	CcSEcCtD
Betahistine—Malaise—Methotrexate—lymphatic system cancer	0.00318	0.00318	CcSEcCtD
Betahistine—Convulsion—Methotrexate—lymphatic system cancer	0.00306	0.00306	CcSEcCtD
Betahistine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.00298	0.00298	CcSEcCtD
Betahistine—Discomfort—Methotrexate—lymphatic system cancer	0.00297	0.00297	CcSEcCtD
Betahistine—Confusional state—Methotrexate—lymphatic system cancer	0.0029	0.0029	CcSEcCtD
Betahistine—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.00288	0.00288	CcSEcCtD
Betahistine—Nervous system disorder—Methotrexate—lymphatic system cancer	0.00282	0.00282	CcSEcCtD
Betahistine—Skin disorder—Methotrexate—lymphatic system cancer	0.0028	0.0028	CcSEcCtD
Betahistine—Dyspnoea—Methotrexate—lymphatic system cancer	0.00257	0.00257	CcSEcCtD
Betahistine—Somnolence—Methotrexate—lymphatic system cancer	0.00256	0.00256	CcSEcCtD
Betahistine—Dyspepsia—Methotrexate—lymphatic system cancer	0.00254	0.00254	CcSEcCtD
Betahistine—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Betahistine—Fatigue—Methotrexate—lymphatic system cancer	0.00248	0.00248	CcSEcCtD
Betahistine—Feeling abnormal—Methotrexate—lymphatic system cancer	0.00237	0.00237	CcSEcCtD
Betahistine—Urticaria—Methotrexate—lymphatic system cancer	0.00229	0.00229	CcSEcCtD
Betahistine—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00212	0.00212	CcSEcCtD
Betahistine—Asthenia—Methotrexate—lymphatic system cancer	0.00207	0.00207	CcSEcCtD
Betahistine—Pruritus—Methotrexate—lymphatic system cancer	0.00204	0.00204	CcSEcCtD
Betahistine—Diarrhoea—Methotrexate—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Betahistine—Dizziness—Methotrexate—lymphatic system cancer	0.0019	0.0019	CcSEcCtD
Betahistine—Vomiting—Methotrexate—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Betahistine—Rash—Methotrexate—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Betahistine—Dermatitis—Methotrexate—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Betahistine—Headache—Methotrexate—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Betahistine—Nausea—Methotrexate—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
